Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
As pharma companies underwrite three-fourths of the FDA’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.
Support Provided By:
By Associated Press
By Jenni Bergal, Stateline
By Lisa Mascaro, Associated Press
By Rob Waters, Kaiser Health News
By Julie Carr Smyth, Associated Press
By Elizabeth Flock
By Matthew Lee, Associated Press
By Nancy Benac, Chad Day, Eric Tucker, Michael Balsamo, Associated Press
By Emily Mullin, STAT
By Josh Boak, Associated Press
By Kelly Field, The Hechinger Report
By Daniel Bush
By Lisa Desjardins
By Joshua Barajas
By Larry Neumeister, Associated Press
By Elaine Ganley, Sylvie Corbet, Associated Press
By Nick Schifrin, Ali Rogin
By Vicky Stein